
  
    
      
        Background_NNP
        Atrial_NNP fibrillation_NN is_VBZ a_DT chaotic_JJ atrial_NN rhythm_NN resulting_VBG
        from_IN abnormal_JJ signal_NN generation_NN and_CC conduction_NN in_IN the_DT
        atria_NN ._. The_DT molecular_JJ basis_NN for_IN atrial_NN fibrillation_NN remains_VBZ
        unknown_JJ ._. It_PRP usually_RB occurs_VBZ in_IN association_NN with_IN structural_JJ
        or_CC metabolic_JJ abnormalities_NNS ._. Atrial_NNP fibrillation_NN ,_, however_RB ,_,
        does_VBZ occur_VB in_IN individuals_NNS with_IN none_NN of_IN these_DT causes_NNS ,_,
        referred_VBD to_TO as_IN lone_JJ atrial_NN fibrillation_NN ._. Recently_RB ,_, we_PRP
        identified_VBD several_JJ families_NNS of_IN multiple_JJ generations_NNS
        affected_VBN with_IN atrial_NN fibrillation_NN with_IN no_DT other_JJ underlying_VBG
        cause_NN detected_VBD ._. This_DT subset_NN of_IN familial_NN atrial_NN fibrillation_NN
        provides_VBZ an_DT opportunity_NN to_TO explore_VB a_DT molecular_JJ basis_NN for_IN
        atrial_NN fibrillation_NN ._.
        Atrial_NNP fibrillation_NN segregates_NNS as_IN an_DT autosomal_NN dominant_JJ
        disease_NN characterized_VBN by_IN atrial_NN fibrillation_NN on_IN an_DT
        electrocardiogram_NN [_NN 1_CD ]_NN ._. We_PRP diagnosed_VBD atrial_NN fibrillation_NN
        in_IN five_CD families_NNS from_IN Spain_NNP in_IN which_WDT the_DT arrhythmia_NN was_VBD the_DT
        primary_JJ manifestation_NN and_CC not_RB associated_VBN with_IN any_DT gross_JJ
        cardiac_JJ or_CC metabolic_JJ abnormality_NN [_NN 1_CD ]_NN ._. Genetic_NNP linkage_NN
        analysis_NN was_VBD performed_VBN and_CC the_DT locus_JJ responsible_JJ for_IN atrial_NN
        fibrillation_NN in_IN our_PRP$ family_NN was_VBD mapped_VBN to_TO 10_CD q_NN 22_CD between_IN
        markers_NNS D_NNP 101786_CD and_CC D_NNP 10_CD S_NNP 1630_CD ,_, an_DT area_NN of_IN about_IN 11_CD cM_NN [_NN 1_CD ]_NN
        ._. We_PRP proceeded_VBD with_IN the_DT candidate_NN gene_NN approach_NN and_CC DLG_NNP 5_CD
        was_VBD on_IN of_IN the_DT genes_NNS mapped_VBN to_TO the_DT critical_JJ region_NN between_IN
        the_DT flanking_VBG markers_NNS [_NN 2_CD ]_NN ._. This_DT gene_NN belongs_VBZ to_TO the_DT MAGUK_NNP
        (_( Membrane_NNP Associated_NNP Gyanylate_NNP Kinase_NNP )_) family_NN of_IN proteins_NNS
        known_VBN to_TO form_VB scaffolds_NNS for_IN proteins_NNS involved_VBN in_IN
        intracellular_NN signal_NN transduction_NN [_NN 2_CD ]_NN ._. The_DT MAGUK_NNP family_NN
        of_IN proteins_NNS has_VBZ been_VBN extensively_RB studied_VBN in_IN recent_JJ years_NNS
        and_CC shown_VBN to_TO play_VB a_DT role_NN in_IN the_DT formation_NN of_IN cell_NN
        junctions_NNS ,_, maintenance_NN of_IN cell_NN shape_NN ,_, [_NN 3_CD 4_CD 5_CD ]_NN and_CC
        clustering_VBG of_IN channel_NN proteins_NNS at_IN the_DT cell_NN surface_NN [_NN 6_CD 7_CD 8_CD
        ]_NN ._. Given_VBN its_PRP$ location_NN in_IN our_PRP$ critical_JJ region_NN and_CC its_PRP$
        function_NN it_PRP was_VBD selected_VBN as_IN a_DT candidate_NN for_IN atrial_NN
        fibrillation_NN ._. A_DT partial_JJ cDNA_NN sequence_NN of_IN DLG_NNP 5_CD (_( GenBank_NNP
        accession_NN #_# AB_NNP 011155_CD )_) of_IN about_IN 5_CD ._. 3_CD K_NN B_NNP was_VBD available_JJ ._. To_TO
        determine_VB if_IN there_EX is_VBZ a_DT mutation_NN responsible_JJ for_IN the_DT
        disease_NN ,_, it_PRP is_VBZ necessary_JJ to_TO have_VB the_DT complete_JJ cDNA_NN ._.
        Furthermore_RB ,_, recognizing_VBG that_IN the_DT responsible_JJ mutation_NN may_MD
        be_VB present_JJ in_IN one_CD of_IN the_DT intron-exon_JJ splice_NN junctions_NNS ,_, it_PRP
        is_VBZ also_RB necessary_JJ to_TO obtain_VB the_DT corresponding_JJ genomic_JJ
        sequence_NN ._. Thus_RB ,_, we_PRP cloned_VBN and_CC sequenced_JJ the_DT cDNA_NN of_IN the_DT
        DLG_NNP 5_CD gene_NN and_CC ,_, from_IN the_DT complete_JJ cDNA_NN sequence_NN ,_, determined_VBD
        the_DT intron-exon_JJ boundaries_NNS of_IN the_DT gene_NN as_RB well_RB as_IN its_PRP$ human_JJ
        tissue_NN expression_NN profile_NN ._.
      
      
        Materials_NNS And_CC Methods_NNP
        
          Northern_JJ blot_NN analysis_NN
          The_DT ESTym_NNP 59_CD b_SYM 11_CD (_( ATCC_NNP clone_NN #_# 409942_CD )_) clone_NN was_VBD
          confirmed_VBN by_IN sequencing_VBG a_DT part_NN of_IN exon_NN 31_CD and_CC exon_NN 32_CD
          with_IN the_DT 3_CD '_POS untranslated_JJ region_NN of_IN the_DT DLG_NNP 5_CD cDNA_NN ._. It_PRP was_VBD
          used_VBN as_IN a_DT probe_NN ,_, labeled_VBN with_IN the_DT random_JJ primer_NN labeling_VBG
          kit_NN from_IN Gibco_NNP with_IN 32_CD P-_NNP dCTP_NN and_CC hybridized_JJ to_TO an_DT adult_NN
          multi_NN tissue_NN RNA_NNP blot_NN from_IN Clontech_NNP ._. Pre_NNP hybridization_NN
          and_CC hybridization_NN were_VBD performed_VBN with_IN Express_NNP Hyb_NNP ._.
          Solution_NN (_( Clontech_NNP )_) using_VBG the_DT manufacturer_NN 's_POS protocol_NN ._.
          The_DT membrane_NN was_VBD washed_VBN once_RB with_IN 2_CD X_NNP SSC_NNP /_NN 0_CD ._. 1_LS %_NN SDS_NNP for_IN 15_CD
          minutes_NNS at_IN room_NN temperature_NN and_CC twice_RB in_IN 0_CD ._. 2_CD %_NN X_NNP SSC_NNP /_NN 0_CD ._. 1_LS %_NN
          SDS_NNP for_IN 20_CD minutes_NNS at_IN 68_CD C_NNP °_NN ._. Membranes_NNP were_VBD exposed_VBN to_TO
          X-_NNP ray_NN film_NN (_( Kodak_NNP )_) overnight_JJ at_IN -_: 80_CD C_NNP ._.
        
        
          Cloning_NNP and_CC sequencing_VBG of_IN the_DT cDNA_NN for_IN DLG_NNP 5_CD
          Using_VBG the_DT RACE_NNP technique_NN (_( Clontech_NNP ,_, Marathon_NNP Ready_NNP
          Heart_NNP cDNA_NN )_) as_IN per_IN manufacturer_NN 's_POS protocol_NN ,_, products_NNS were_VBD
          generated_VBN using_VBG primers_NNS designed_VBN in_IN the_DT 5_CD '_POS end_NN of_IN the_DT
          described_VBN cDNA_NN DLG_NNP 5_CD ._. Nested_NNP RACE_NNP was_VBD performed_VBN on_IN the_DT
          product_NN and_CC the_DT generated_VBN PCR_NNP product_NN cloned_VBN by_IN using_VBG TA_NNP
          cloning_VBG (_( Invitrogen_NNP )_) ._. The_DT clones_NNS were_VBD plated_JJ on_IN kanamycin_NN
          IPTG_NNP plates_NNS ._. Colonies_NNP were_VBD picked_VBN and_CC grown_VBN in_IN 5_CD ml_NN
          LB-Kan_NNP broth_NN ._. Subsequent_JJ to_TO miniprep_NN using_VBG Qiagen_NNP
          Miniprep_NNP Kit_NNP (_( QIAgen_NNP ,_, Valencia_NNP ,_, CA_NNP )_) ,_, the_DT clones_NNS were_VBD
          sequenced_JJ on_IN the_DT ABI_NNP 310_CD genetic_JJ analyzer_NN using_VBG the_DT Big_NNP
          Dye_NNP terminator_NN chemistry_NN ._. The_DT Race_NN primers_NNS are_VBP :_: Primer_NNP A_DT
          5_CD '_POS GCATACACTCCATTCTCCAGACTGATGC_NNP 3_CD '_POS ;_: primer_NN B_NNP (_( nested_JJ to_TO
          primer_NN A_DT )_) 5_CD '_POS CACTCATGATGAGCTTGTACTCGCTGTA_NNP 3_CD '_POS ;_: primer_NN F_NN
          5_CD '_POS GTGTGGTAGAAGTCAGTCTCCTTGGCCA_NNP 3_CD '_POS ;_: primer_NN E_NNP (_( nested_JJ to_TO
          primer_NN F_NN )_) and_CC 5_CD '_POS GCTGAATGGAGAGGTTCTCCACCTTCTC_NNP 3_CD ._. We_PRP
          generated_VBD additional_JJ 1_CD ._. 702_CD KB_NNP of_IN cDNA_NN for_IN this_DT gene_NN for_IN a_DT
          total_JJ cDNA_NN length_NN of_IN 7_CD ._. 194_CD KB_NNP ._. The_DT cDNA_NN generated_VBN had_VBD an_DT
          overlap_VB of_IN 305_CD bp_NN with_IN the_DT published_VBN DLG_NNP 5_CD cDNA_NN (_( Genbank_NNP
          Acc_NNP ._. #_# AB_NNP 011155_CD )_) in_IN the_DT 5_CD '_POS end_NN of_IN the_DT gene_NN ._. We_PRP further_RBR
          cloned_VBN ,_, in_IN two_CD pieces_NNS with_IN an_DT overlap_VB of_IN 226_CD bp_NN ,_, the_DT cDNA_NN
          covering_VBG about_IN 2_CD Kb_NNP of_IN this_DT gene_NN in_IN the_DT 5_CD '_POS end_NN from_IN bp_NN
          1_CD -_: 2007_CD of_IN the_DT cDNA_NN ._. The_DT clones_NNS were_VBD :_: Clone_NNP T_NN /_NN F_NN 1_CD -_: 471_CD bp_NN
          of_IN 7_CD ._. 194_CD Kb_NNP cDNA_NN [_NN using_VBG primers_NNS T_NN 5_CD '_POS
          GGTCTCAACTTAAACTCCAGCACCACGA_NNP 3_CD '_POS with_IN the_DT primer_NN F_NN ]_NN and_CC
          clone_NN G_NNP /_NN A_DT 246_CD -_: 2007_CD bp_NN of_IN 7_CD ._. 194_CD Kb_NNP cDNA_NN [_NN using_VBG primer_NN G_NNP 5_CD '_POS
          GAGAAGGTGGAG_NNP AACCTCTCCATTCAGC_NNP 3_CD '_POS with_IN primer_NN A_DT ]_NN ._. As_IN
          mentioned_VBN there_EX is_VBZ an_DT overlap_VB of_IN 226_CD bp_NN (_( 246_CD -_: 471_CD bp_NN of_IN
          7_CD ._. 194_CD KB_NNP cDNA_NN )_) between_IN the_DT two_CD clones_NNS ._. We_PRP performed_VBD
          multiple_JJ RACE_NNP reactions_NNS using_VBG heart_NN and_CC placental_NN cDNA_NN
          until_IN no_DT further_JJ extension_NN was_VBD made_VBN to_TO the_DT cDNA_NN
          suggesting_VBG we_PRP had_VBD reached_VBN the_DT end_NN of_IN the_DT gene_NN ._.
          In_IN addition_NN to_TO RACE_NNP ,_, we_PRP also_RB used_VBD PCR_NNP based_VBD heart_NN
          library_NN screening_NN (_( Origene_NNP Technologies_NNPS ,_, Cat_NNP #_# 1001_CD )_) ._. We_PRP
          isolated_VBD a_DT clone_NN that_WDT matched_VBD our_PRP$ RACE_NNP clone_NN which_WDT gave_VBD
          confirmation_NN to_TO the_DT cDNA_NN sequence_NN generated_VBN by_IN the_DT RACE_NNP
          technique_NN ._. We_PRP used_VBD Sequencer_NNP 3_CD ._. 1_CD program_NN to_TO assemble_VB our_PRP$
          sequences_NNS ._. There_EX was_VBD considerable_JJ overlap_VB between_IN the_DT 305_CD
          bp_NN fragment_NN of_IN the_DT new_JJ sequence_NN and_CC that_IN of_IN the_DT published_VBN
          cDNA_NN of_IN DLG_NNP 5_CD ._. We_PRP identified_VBD an_DT ORF_NNP with_IN a_DT stop_NN codon_NN
          preceding_VBG it_PRP indicating_VBG we_PRP had_VBD obtained_VBN the_DT entire_JJ coding_VBG
          region_NN of_IN the_DT gene_NN ._. The_DT complete_JJ cDNA_NN sequence_NN has_VBZ been_VBN
          submitted_VBN to_TO Genbank_NNP ,_, Accession_NNP Number_NNP AF_NNP 352034_CD ._.
        
        
          In-_NNP Silicon_NNP mapping_NN and_CC genomic_JJ organisation_NN Of_IN
          DLG_NNP 5_CD
          The_DT newly_RB generated_VBN DLG_NNP 5_CD cDNA_NN sequence_NN (_( 7_CD ._. 195_CD Kb_NNP )_) was_VBD
          subjected_VBN to_TO a_DT search_NN for_IN homology_NN to_TO genomic_JJ sequences_NNS
          in_IN Genbank_NNP using_VBG BLASTN_NNP algorithm_NN on_IN Search_NNP Launcher_NNP ,_,
          available_JJ at_IN Molecular_NNP Biology_NNP Computational_NNP Resources_NNPS
          (_( MBCR_NNP )_) server_NN ,_, Baylor_NNP College_NNP of_IN Medicine_NNP (_( BCM_NNP )_)
          www_NN ._. mbcr_NN ._. bcm_NN ._. tmc_NN ._. edu_NN ._. Homologous_NNP sequences_NNS were_VBD
          identified_VBN on_IN BAC_NNP 651_CD c_SYM 23_CD (_( Acc_NNP ._. No_UH ._. AC_NNP 013252_CD )_) and_CC BAC_NNP
          126_CD h_NN 7_CD (_( Acc_NNP ._. No_UH ._. AL_NNP 391421_CD )_) ._. The_DT Sequencer_NNP 3_CD ._. 1_CD program_NN was_VBD
          employed_VBN to_TO assemble_VB genomic_JJ sequences_NNS from_IN these_DT BACs_NNP
          and_CC to_TO map_VB the_DT cDNA_NN to_TO these_DT sequences_NNS ._. The_DT genomic_JJ
          sequences_NNS for_IN the_DT gene_NN were_VBD deposited_VBN in_IN GenBank_NNP with_IN
          Accession_NNP Number_NNP AF_NNP 352033_CD ._.
        
        
          Analysis_NNP of_IN patient_NN DNA_NNP
          Using_VBG available_JJ genomic_JJ sequences_NNS ,_, primers_NNS were_VBD
          designed_VBN to_TO analyze_VB the_DT patient_JJ DNA_NNP ._. Primers_NNP were_VBD
          anchored_VBN in_IN introns_NNS and_CC PCR_NNP products_NNS generated_VBN from_IN
          genomic_JJ DNA_NNP of_IN patients_NNS ._. PCR_NNP was_VBD performed_VBN with_IN 200_CD ng_NN
          genomic_JJ DNA_NNP ,_, 50_CD μM_NN each_DT deoxynucleotide_NN triphosphate_NN ,_, 02_CD
          μM_NN of_IN forward_RB and_CC reverse_VB primers_NNS each_DT and_CC 2_CD ._. 5_CD units_NNS of_IN
          Taq_NNP Polymerase_NNP (_( life_NN Technologies_NNPS )_) ._. PCR_NNP was_VBD done_VBN on_IN
          PE_NNP 9600_CD or_CC PE_NNP 9700_CD thermocycler_NN ._. Sequencing_NNP reactions_NNS were_VBD
          performed_VBN using_VBG fluorescent_NN labeled_VBD Big_NNP Dye_NNP terminator_NN
          (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) on_IN a_DT PE_NNP 9600_CD
          thermocycler_NN ._. Each_DT reaction_NN was_VBD then_RB cleaned_VBN over_IN the_DT
          Edge_NNP Biosystems_NNP column_NN and_CC subsequently_RB sequenced_JJ on_IN an_DT
          ABI_NNP 310_CD or_CC ABI_NNP 377_CD genetic_JJ analyzer_NN ._. Sequences_NNP were_VBD
          assembled_VBN using_VBG Sequencer_NNP 3_CD ._. 1_CD program_NN ._.
        
        
          Use_NN of_IN a_DT novel_NN technique_NN to_TO rule_VB out_IN deletion_NN
          mutations_NNS
          We_PRP utilized_JJ a_DT newly_RB available_JJ somatic_JJ cell_NN hybrid_JJ
          technique_NN from_IN GMP_NNP Genetics_NNP ,_, Inc_NNP ._. [_NN 9_CD ]_NN to_TO obtain_VB haploid_NN
          cell_NN lines_NNS ._. In_IN brief_JJ ,_, this_DT technology_NN provides_VBZ a_DT means_NN
          whereby_WRB the_DT two_CD homologous_RB chromosomes_NNS are_VBP separated_JJ and_CC
          isolated_VBN into_IN separate_JJ cell_NN lines_NNS ._. Our_PRP$ affected_VBN patient_NN 's_POS
          diploid_NN leucocytic_JJ cell_NN line_NN was_VBD converted_VBN to_TO haploid_NN
          somatic_JJ cell_NN hybrid_JJ lines_NNS ._. The_DT hybrid_JJ cell_NN lines_NNS were_VBD
          screened_VBD to_TO identify_VB those_DT cell_NN lines_NNS that_WDT contain_VBP the_DT
          chromosome_NN 10_CD homologues_NNS ._. We_PRP further_RBR confirmed_VBN by_IN
          genotyping_VBG that_IN the_DT DNA_NNP of_IN one_CD of_IN these_DT haploid_NN lines_NNS had_VBD
          the_DT alleles_NNS segregating_VBG with_IN the_DT disease_NN ._. Thus_RB ,_, if_IN a_DT
          mutation_NN in_IN the_DT DLG_NNP 5_CD gene_NN is_VBZ responsible_JJ for_IN the_DT disease_NN
          it_PRP would_MD be_VB in_IN this_DT cell_NN line_NN ._. We_PRP then_RB performed_VBD PCR_NNP
          using_VBG primers_NNS anchored_VBN in_IN the_DT introns_NNS of_IN DLG_NNP 5_CD for_IN each_DT of_IN
          the_DT exons_NNS on_IN both_DT the_DT normal_JJ haploid_NN DNA_NNP and_CC the_DT disease_NN
          bearing_NN haploid_NN DNA_NNP ._. The_DT presence_NN of_IN amplification_NN
          products_NNS from_IN both_DT haploid_NN lines_NNS would_MD detect_VB any_DT exon_NN
          deletion_NN that_WDT may_MD have_VB eluded_VBD detection_NN by_IN PCR_NNP from_IN
          genomic_JJ DNA_NNP ._.
        
      
      
        Results_NNS and_CC discussion_NN
        
          Human_JJ tissue_NN expression_NN patterns_NNS of_IN DLG_NNP 5_CD
          The_DT expression_NN pattern_NN of_IN the_DT DLG_NNP 5_CD gene_NN was_VBD analyzed_VBN
          in_IN multiple_JJ adult_NN human_JJ tissues_NNS by_IN Northern_NNP Blot_NNP Analysis_NNP
          using_VBG as_IN a_DT probe_NN the_DT ATCC_NNP clone_NN #_# 409942_CD (_( EST_NNP ym_NN 59_CD b_SYM 11_CD )_)
          with_IN insert_NN an_DT size_NN of_IN 2_CD ._. 386_CD Kb_NNP which_WDT contains_VBZ exon_NN 31_CD
          and_CC 32_CD with_IN 3_CD '_POS untranslated_JJ region_NN of_IN the_DT gene_NN ._. A_DT
          twenty-four_JJ hour_NN exposure_NN showed_VBD abundant_JJ expression_NN in_IN
          placenta_NN with_IN minimal_JJ expression_NN in_IN skeletal_NN muscle_NN ,_,
          liver_NN ,_, kidney_NN and_CC pancreas_NN and_CC no_DT expression_NN in_IN heart_NN
          (_( data_NNS not_RB shown_VBN )_) ._. Exposure_NNP for_IN six_CD days_NNS showed_VBD expression_NN
          in_IN heart_NN ,_, no_DT expression_NN in_IN the_DT brain_NN and_CC abundant_JJ
          expression_NN in_IN placenta_NN as_IN shown_VBN in_IN Figure_NN 1_CD ._. We_PRP observed_VBD
          a_DT single_JJ transcript_NN of_IN approximately_RB 7_CD ._. 2_CD Kb_NNP thus_RB ,_, the_DT
          published_VBN sequence_NN of_IN the_DT cDNA_NN for_IN the_DT DLG_NNP 5_CD gene_NN was_VBD
          incomplete_JJ ._.
        
        
          Cloning_NNP and_CC sequencing_VBG of_IN the_DT DLG_NNP 5_CD cDNA_NN
          On_IN Northern_NNP Blot_NNP Analysis_NNP a_DT single_JJ transcript_NN of_IN
          approximately_RB 7_CD ._. 2_CD Kb_NNP was_VBD observed_VBN ._. Using_VBG Race_NN Technique_NNP
          on_IN Heart_NNP cDNA_NN and_CC heart_NN library_NN screening_NN as_IN described_VBN
          above_IN we_PRP characterized_VBD the_DT entire_JJ cDNA_NN of_IN 7_CD ._. 195_CD Kb_NNP :_: a_DT
          5_CD '_POS UTR_NNP from_IN bp_NN 1_CD to_TO 94_CD ,_, ORF_NNP from_IN bp_NN 95_CD -_: 5547_CD and_CC 3_CD '_POS UTR_NNP from_IN
          bp_NN 5548_CD -_: 7195_CD ._. The_DT translation_NN start_NN codon_NN of_IN the_DT cDNA_NN is_VBZ
          at_IN bp_NN 118_CD in_IN exon_NN 2_CD and_CC the_DT stop_NN codon_NN is_VBZ at_IN bp_NN 5545_CD in_IN
          exon_NN 32_CD ._. As_IN multiple_JJ clones_NNS were_VBD sequenced_JJ after_IN RACE_NNP ,_, 2_CD
          distinct_JJ forms_NNS were_VBD observed_VBN :_: one_CD with_IN a_DT 12_CD nucleotide_NN
          deletion_NN in_IN the_DT beginning_NN of_IN exon_NN 4_CD and_CC the_DT form_NN without_IN
          the_DT deletion_NN ._. The_DT deletion_NN did_VBD not_RB result_VB in_IN any_DT change_NN
          in_IN the_DT ORF_NNP of_IN the_DT gene_NN ._.
        
        
          Search_NNP for_IN ESTS_NNP homologous_RB to_TO the_DT cDNA_NN
          Using_VBG Search_NNP Launcher_NNP available_JJ on_IN the_DT Molecular_NNP
          Biology_NNP Computational_NNP Resources_NNPS (_( MBCR_NNP )_) server_NN at_IN Baylor_NNP
          College_NNP of_IN Medicine_NNP (_( BCM_NNP )_) www_NN ._. mbcr_NN ._. bcm_NN ._. tmc_NN ._. eduhomology_NN
          searches_NNS on_IN the_DT new_JJ cDNA_NN sequence_NN against_IN DBEST_NNP database_NN
          identified_VBD several_JJ ESTs_NNP ,_, {_( Acc_NNP ._. #_# BF_NNP 357671_CD and_CC Acc_NNP ._.
          #_# bf_NN 336740_CD }_) which_WDT overlap_VBP each_DT other_JJ and_CC match_VB the_DT new_JJ
          cDNA_NN
        
        
          Determining_VBG the_DT intron_NN exon_NN boundaries_NNS of_IN
          DLG_NNP 5_CD
          We_PRP mapped_VBN 31_CD exons_NNS (_( 2_CD -_: 32_CD )_) of_IN the_DT 7_CD ._. 195_CD Kb_NNP of_IN the_DT cDNA_NN
          to_TO a_DT genomic_JJ region_NN spanning_VBG about_IN 79_CD Kb_NNP ._. We_PRP could_MD not_RB
          map_VB 1_CD -_: 94_CD bp_NN (_( 5_CD '_POS UTR_NNP )_) on_IN to_TO the_DT genomic_JJ region_NN ._. This_DT may_MD be_VB
          because_IN none_NN of_IN these_DT BACs_NNP are_VBP completely_RB sequenced_JJ in_IN
          Genbank_NNP and_CC there_EX are_VBP still_RB gaps_NNS in_IN the_DT genomic_JJ
          sequencing_VBG ._. Attempts_NNS at_IN direct_JJ BAC_NNP walking_VBG to_TO place_VB these_DT
          nucleotides_NNS were_VBD unsuccessful_JJ ,_, perhaps_RB because_IN these_DT
          regions_NNS of_IN genomic_JJ DNA_NNP are_VBP difficult_JJ to_TO sequence_NN due_JJ to_TO
          its_PRP$ secondary_JJ structure_NN ._. The_DT details_NNS of_IN the_DT genomic_JJ
          organization_NN of_IN the_DT gene_NN are_VBP shown_VBN in_IN Table_NNP 1_CD and_CC Figure_NN
          2_CD ._. All_DT but_CC two_CD of_IN the_DT resulting_VBG intron-exon_JJ boundaries_NNS
          concur_VB with_IN the_DT typical_JJ splice_NN donor_NN and_CC acceptor_NN
          motif-_NN GT_NNP /_NN AG_NNP ._. The_DT sequences_NNS around_IN each_DT splice_NN site_NN are_VBP
          shown_VBN in_IN Table_NNP 2_CD ._.
        
        
          Determining_VBG the_DT functional_JJ domains_NNS in_IN DLG_NNP 50_CD
          The_DT MAGUK_NNP family_NN of_IN proteins_NNS [_NN 2_CD 10_CD ]_NN have_VBP
          characteristic_JJ domains_NNS which_WDT are_VBP present_JJ in_IN DLG_NNP 5_CD :_: PDZ_NNP 1_CD at_IN
          bp_NN 3763_CD -_: 4074_CD ,_, PDZ_NNP 2_CD domain_NN 4186_CD -_: 4518_CD bp_NN ,_, SH_NNP 3_CD domain_NN bp_NN
          4570_CD -_: 4782_CD and_CC the_DT GUK_NNP domain_NN at_IN bp_NN 4915_CD -_: 5539_CD (_( Figure_NN
          2_LS )_) ._.
          Several_JJ domains_NNS were_VBD identified_VBN in_IN the_DT novel_NN cDNA_NN
          using_VBG MOTIF_NNP at_IN SEQ_NNP WEB_NNP ._. A_DT single_JJ repeat_NN unit_NN of_IN the_DT
          Regulator_NNP of_IN Chromosomal_NNP Chromatin_NNP (_( RCC_NNP 1_LS )_) domain_NN was_VBD
          detected_VBN starting_VBG at_IN bp_NN 4333_CD ._. RCC_NNP 1_CD is_VBZ a_DT eukaryotic_JJ
          protein_NN that_WDT has_VBZ seven_CD tandem_JJ repeats_VBZ units_NNS which_WDT
          comprise_VBP a_DT domain_NN of_IN 50_CD -_: 60_CD amino_JJ acids_NNS ._. This_DT domain_NN binds_NNS
          to_TO chromatin_NN and_CC interacts_NNS with_IN Ran_NNP ,_, a_DT nuclear_JJ
          GTP-binding_NNP protein_NN that_IN stimulates_NNS a_DT guanine_NN nucleotide_NN
          dissociation_NN ._. Thus_RB ,_, RCC_NNP 1_CD probably_RB plays_VBZ a_DT role_NN as_IN a_DT gene_NN
          regulator_NN ._. Only_RB one_CD repeat_NN unit_NN is_VBZ present_JJ in_IN DLG_NNP 5_CD which_WDT
          makes_VBZ it_PRP difficult_JJ to_TO predict_VB whether_IN it_PRP also_RB has_VBZ such_JJ
          gene_NN regulating_VBG function_NN ._.
          A_DT prenyl_NN group-binding_JJ site_NN (_( CAAX_NNP box_NN )_) was_VBD also_RB
          detected_VBN starting_VBG at_IN 5536_CD bp_NN ._. A_DT number_NN of_IN proteins_NNS are_VBP
          post_NN translationally_RB modified_VBN by_IN the_DT attachment_NN of_IN either_DT
          a_DT fresnyl_NN or_CC a_DT geranyl-geranyl_JJ group_NN to_TO a_DT cysteine_NN
          residue_NN ._. This_DT modification_NN occurs_VBZ on_IN a_DT cysteine_NN residue_NN ,_,
          three_CD residues_NNS proximal_NN to_TO the_DT C-_NNP terminus_JJ with_IN two_CD
          aliphatic_JJ amino_JJ acids_NNS separating_VBG the_DT cysteine_NN from_IN the_DT
          C-_NNP terminus_JJ (_( hence_RB the_DT term_NN CAAX_NNP box_NN )_) ._. Certain_JJ proteins_NNS
          such_JJ as_IN Ras_NNP proteins_NNS and_CC the_DT Ras-like_NNP protein_NN Rho_NNP ,_,
          nuclear_JJ lamins_NNS A_DT and_CC B_NNP and_CC some_DT G_NNP protein_NN alpha_NN subunits_NNS
          have_VBP this_DT modification_NN ._. These_DT proteins_NNS are_VBP involved_VBN in_IN
          intracellular_NN signal_NN transduction_NN ._. This_DT is_VBZ another_DT
          mechanism_NN by_IN which_WDT DLG_NNP 5_CD may_MD be_VB involved_VBN in_IN intracellular_NN
          signal_NN transduction_NN ._. In_IN addition_NN to_TO these_DT domains_NNS there_RB
          are_VBP two_CD leucine_NN zippers_NNS starting_VBG at_IN base_NN pairs_NNS 484_CD and_CC
          505_CD suggesting_VBG protein-protein_JJ interaction_NN ._.
        
        
          Exclusion_NNP of_IN DLG_NNP 50_CD as_IN a_DT candidate_NN for_IN familial_NN
          atrial_NN fibrillation_NN in_IN our_PRP$ family_NN
          The_DT exons_NNS and_CC flanking_VBG intronic_JJ sequences_NNS of_IN DLG_NNP 50_CD
          were_VBD amplified_VBN by_IN PCR_NNP and_CC sequenced_JJ in_IN four_CD members_NNS of_IN
          the_DT family_NN ,_, two_CD affected_VBN and_CC two_CD normals_NNS ._. There_EX were_VBD no_DT
          missense_NN or_CC nonsense_NN mutations_NNS segregating_VBG with_IN the_DT
          disease_NN in_IN either_DT the_DT coding_VBG regions_NNS or_CC splice_NN junctions_NNS
          of_IN this_DT gene_NN ._. To_TO exclude_VB a_DT large_JJ deletion_NN that_WDT might_MD have_VB
          eluded_VBD amplification_NN from_IN diploid_NN DNA_NNP by_IN PCR_NNP sequencing_VBG
          was_VBD performed_VBN on_IN the_DT haploid_NN cell_NN lines_NNS and_CC no_DT mutation_NN
          was_VBD identified_VBN ._. Thus_RB ,_, DLG_NNP 50_CD is_VBZ excluded_VBN as_IN a_DT possible_JJ
          cause_NN of_IN familial_NN atrial_NN fibrillation_NN in_IN these_DT
          families_NNS ._.
          Utilizing_NNP the_DT available_JJ partial_JJ cDNA_NN sequence_NN ,_, we_PRP
          confirmed_VBD the_DT localization_NN of_IN DLG_NNP 5_CD to_TO the_DT locus_JJ for_IN
          atrial_NN fibrillation_NN at_IN 10_CD q_NN 22_CD and_CC subsequently_RB cloned_VBN and_CC
          sequenced_JJ the_DT DLG_NNP 5_CD gene_NN which_WDT spanned_VBD 79_CD KB_NNP ._. The_DT
          available_JJ 5_CD ._. 5_CD KB_NNP cDNA_NN sequence_NN was_VBD extended_VBN by_IN RACE_NNP and_CC
          confirmed_VBD on_IN northern_JJ analysis_NN to_TO be_VB about_IN 7_CD ._. 2_CD KB_NNP ._. The_DT
          genomic_JJ structure_NN of_IN the_DT DLG_NNP 5_CD was_VBD determined_VBN to_TO consist_VB
          of_IN 32_CD exons_NNS and_CC shown_VBN to_TO have_VB ubiquitous_JJ human_JJ tissue_NN
          expression_NN including_VBG placenta_NN ,_, heart_NN ,_, skeletal_NN muscle_NN ,_,
          liver_NN and_CC pancreas_NN ,_, with_IN placenta_NN being_VBG the_DT tissue_NN of_IN
          strongest_JJS expression_NN ._. Exclusion_NNP of_IN a_DT deletion_NN from_IN the_DT
          haploid_NN cell_NN lines_NNS confirmed_VBD the_DT absence_NN of_IN any_DT mutation_NN
          and_CC thus_RB ,_, DLG_NNP 5_CD was_VBD excluded_VBN as_IN a_DT cause_NN for_IN the_DT atrial_NN
          fibrillation_NN in_IN these_DT families_NNS ._. Two_CD distinct_JJ transcripts_NNS
          of_IN DLG_NNP 5_CD were_VBD observed_VBN differing_VBG by_IN only_RB 12_CD bp_NN ,_, which_WDT
          would_MD predict_VB the_DT addition_NN (_( or_CC deletion_NN )_) of_IN 4_CD amino_JJ
          acids_NNS ,_, but_CC would_MD not_RB alter_VB the_DT translation_NN frame_NN of_IN the_DT
          gene_NN ._.
          The_DT DLG_NNP 5_CD gene_NN encodes_NNS for_IN a_DT protein_NN that_WDT is_VBZ a_DT member_NN
          of_IN the_DT MAGUK_NNP (_( Membrane_NNP Associated_NNP Guan_NNP late_JJ Kinase_NNP
          homologs_NNS )_) family_NN of_IN proteins_NNS located_VBN in_IN the_DT plasma_NN
          membrane_NN [_NN 2_CD ]_NN ._. MAGUK_NNP is_VBZ a_DT new_JJ family_NN of_IN proteins_NNS that_WDT
          act_NN as_IN a_DT molecular_JJ scaffold_NN for_IN intracellular_NN signaling_VBG
          pathways_NNS [_NN 11_CD ]_NN ._. The_DT MAGUK_NNP family_NN of_IN proteins_NNS is_VBZ
          characterized_VBN by_IN domains_NNS that_WDT interact_NN with_IN other_JJ
          proteins_NNS to_TO create_VB an_DT assembly_NN of_IN large_JJ multi-protein_JJ
          complexes_NNS [_NN 10_CD ]_NN ._. The_DT PDZ_NNP (_( PSD-_NNP 95_CD ,_, DLG_NNP and_CC ZO-_NNP 1_LS )_) domains_NNS
          are_VBP the_DT best_RBS characterized_VBN for_IN their_PRP$ binding_JJ to_TO the_DT
          C-_NNP terminal_NN region_NN of_IN channels_NNS and_CC transmembrane_NN proteins_NNS
          [_NN 11_CD ]_NN ._. Usually_RB each_DT protein_NN has_VBZ 1_CD -_: 3_CD copies_NNS of_IN such_JJ
          domains_NNS [_NN 8_CD 12_CD 13_CD ]_NN ._. The_DT SH_NNP 3_CD domain_NN (_( Src_NNP homology_NN 3_LS )_) are_VBP
          present_JJ in_IN proteins_NNS that_WDT couple_NN transmembrane_NN receptors_NNS
          to_TO signaling_VBG molecules_NNS [_NN 14_CD ]_NN ._. The_DT presence_NN of_IN this_DT
          domain_NN in_IN MAGUKs_NNP increases_VBZ their_PRP$ possibilities_NNS of_IN
          interacting_VBG with_IN signaling_VBG pathways_NNS ._. The_DT GUK_NNP domain_NN shows_VBZ
          a_DT high_JJ degree_NN of_IN similarity_NN to_TO guanylate_NN kinase_NN enzyme_NN ,_,
          which_WDT converts_VBZ GMP_NNP to_TO GDP_NNP using_VBG ATP_NNP as_IN a_DT phosphate_NN donor_NN ._.
          The_DT dlg-like_JJ MAGUKs_NNP do_VBP not_RB have_VB kinase_NN activity_NN [_NN 15_CD ]_NN ._.
          Furthermore_RB this_DT domain_NN has_VBZ been_VBN shown_VBN to_TO interact_NN with_IN
          other_JJ proteins_NNS [_NN 16_CD 17_CD 18_CD ]_NN ._. MAGUKs_NNP function_NN by_IN binding_VBG
          to_TO the_DT transmembrane_NN proteins_NNS at_IN the_DT cytoplasmic_JJ side_NN and_CC
          to_TO other_JJ signal_NN transduction_NN proteins_NNS and_CC thus_RB appear_VB to_TO
          provide_VB the_DT platform_NN for_IN efficient_JJ and_CC specific_JJ signal_NN
          interactions_NNS between_IN the_DT different_JJ components_NNS of_IN the_DT
          signaling_VBG pathway_NN ._. Acting_NN as_IN scaffold_NN proteins_NNS ,_, these_DT
          proteins_NNS play_VBP a_DT pivotal_JJ role_NN in_IN creating_VBG an_DT efficient_JJ
          signaling_VBG pathway_NN by_IN localizing_VBG the_DT signaling_VBG molecules_NNS
          at_IN regions_NNS of_IN cell_NN surface_NN preferentially_RB exposed_VBD to_TO the_DT
          ligand_NN ,_, and_CC by_IN spatially_RB restricting_VBG the_DT molecules_NNS to_TO
          provide_VB specific_JJ downstream_JJ responses_NNS ._.
          The_DT DLG_NNP 5_CD gene_NN encodes_NNS for_IN 2_CD PDZ_NNP domains_NNS ,_, with_IN another_DT
          region_NN in_IN the_DT N-_NNP terminus_JJ having_VBG very_RB weak_JJ homology_NN to_TO an_DT
          additional_JJ two_CD PDZ_NNP domains_NNS ._. It_PRP is_VBZ notable_JJ that_IN the_DT PDZ_NNP
          domains_NNS predicted_VBD for_IN the_DT DLG_NNP 5_CD protein_NN do_VBP not_RB have_VB the_DT
          GLGF_NNP motif_NN [_NN 2_CD ]_NN ,_, present_JJ in_IN most_JJS members_NNS of_IN the_DT MAGUK_NNP
          family_NN ._. This_DT motif_NN helps_VBZ in_IN the_DT binding_VBG of_IN the_DT MAGUK_NNP with_IN
          the_DT C-_NNP terminus_JJ of_IN proteins_NNS that_WDT have_VBP the_DT consensus_NN E_NNP
          (_( S_NNP /_NN T_NN )_) ×_NN (_( V_NNP /_NN l_NN )_) motif_NN [_NN 19_CD ]_NN ._. However_RB the_DT studies_NNS on_IN the_DT
          Drosophila_NNP protein_NN InaD_NNP ,_, which_WDT also_RB has_VBZ a_DT PDZ_NNP domain_NN ,_,
          show_NN that_WDT are_VBP other_JJ targets_NNS for_IN the_DT PDZ_NNP domain_NN that_WDT do_VBP
          not_RB have_VB the_DT consensus_NN C-_NNP terminus_JJ binding_JJ motif_NN [_NN 20_CD ]_NN ._.
          Thus_RB in_IN DLG_NNP 5_CD the_DT PDZ_NNP domain_NN may_MD be_VB binding_JJ to_TO other_JJ
          targets_NNS that_WDT do_VBP not_RB require_VB the_DT classic_JJ GLGF_NNP motif_NN for_IN
          interaction_NN ._. Like_IN other_JJ members_NNS of_IN this_DT family_NN DLG_NNP 5_CD also_RB
          has_VBZ one_CD SH_NNP 3_CD and_CC GUK_NNP domain_NN ._. In_IN addition_NN it_PRP has_VBZ two_CD
          leucine_NN zippers_NNS and_CC an_DT RCC_NNP 1_CD domain_NN that_WDT represents_VBZ other_JJ
          potential_JJ protein-protein_JJ interactions_NNS ._.
          Previously_RB reported_VBD MAGUKs_NNP have_VBP been_VBN studied_VBN for_IN these_DT
          interactions_NNS ,_, and_CC elegant_JJ work_NN has_VBZ shown_VBN one_CD of_IN its_PRP$
          members_NNS ,_, p_NN 55_CD ,_, to_TO form_VB a_DT ternary_JJ complex_NN that_IN links_VBZ the_DT
          cytoskeleton_NN and_CC the_DT plasma_NN membrane_NN to_TO maintain_VB proper_JJ
          cell_NN shape_NN [_NN 3_CD ]_NN ._. Also_RB there_EX is_VBZ significant_JJ evidence_NN
          that_IN MAGUKs_NNP are_VBP active_JJ in_IN protein_NN clustering_VBG especially_RB
          of_IN ion_NN channels_NNS and_CC membrane_NN bound_VBN receptors_NNS [_NN 6_CD ]_NN ._. This_DT
          interaction_NN has_VBZ been_VBN proven_VBN by_IN experiments_NNS in_IN which_WDT DLG_NNP 5_CD
          mutants_NNS show_VBP loss_NN of_IN clustering_VBG of_IN the_DT Shaker_NNP channels_NNS at_IN
          neuromuscular_NN junction_NN [_NN 6_CD ]_NN ._. Mammalian_NNP PSD-_NNP 95_CD is_VBZ a_DT
          MAGUK_NNP which_WDT binds_NNS Kir_NNP 4_CD ._. 1_LS ,_, an_DT inwardly_RB rectifying_VBG K_NNP
          +_NN channel_NN expressed_VBD in_IN glial_NN cells_NNS and_CC also_RB clusters_NNS it_PRP to_TO
          cell_NN membranes_NNS in_IN vitro_NN [_NN 21_CD ]_NN ._. Thus_RB MAGUKs_NNP may_MD regulate_VB
          the_DT distribution_NN and_CC also_RB the_DT function_NN of_IN transmembrane_NN
          receptors_NNS and_CC channels_NNS ._.
        
      
      
        Conclusions_NNP
        Given_VBN these_DT observations_NNS ,_, its_PRP$ pattern_NN of_IN expression_NN in_IN
        the_DT human_JJ adult_NN heart_NN ,_, we_PRP considered_VBD it_PRP to_TO be_VB an_DT excellent_JJ
        candidate_NN for_IN the_DT familial_NN atrial_NN fibrillation_NN and_CC
        evaluated_VBD it_PRP in_IN our_PRP$ family_NN by_IN sequencing_VBG ._. We_PRP have_VBP ruled_VBN out_IN
        functional_JJ mutation_NN in_IN the_DT coding_VBG region_NN and_CC splice_NN
        junction_NN as_RB well_RB as_IN any_DT exon_NN deletion_NN as_IN possible_JJ cause_NN of_IN
        the_DT disease_NN in_IN this_DT family_NN ._. This_DT gene_NN remains_VBZ an_DT
        interesting_JJ candidate_NN for_IN other_JJ inherited_VBN cardiac_JJ
        diseases_NNS ._.
      
    
  
